Welcome to our dedicated page for Covista SEC filings (Ticker: CVSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Covista Inc. filings document current reports on operating results, academic performance, investor communications and strategic progress for its healthcare education portfolio. Recent Form 8-K records furnish quarterly results releases, enrollment metrics, revenue and earnings measures, fiscal guidance, share repurchase activity, debt refinancing references and institutional updates for Chamberlain and Walden.
The company's Regulation FD disclosures also include investor newsletters describing milestones, partnerships, workforce-related initiatives and operational progress. Covista's filing record identifies public-company disclosure themes tied to results of operations, capital allocation, governance signatories, cautionary forward-looking statements and the company's current identity as a NYSE-listed healthcare educator.
Covista Inc. is listed as the issuer for a notice covering a proposed sale of 5,291 Common securities through Goldman Sachs & Co. LLC with a sale date of July 13, 2026 on the NYSE.
The 5,291 securities were acquired on September 8, 2025 as compensation in the form of Restricted Stock Units from Covista Inc. Over the prior three months, the Stephen Wayne Beard Trust u/a/d 09/03/2015, with Stephen W. Beard Jr. as trustee, sold 15,874 Common securities on May 8, 2026, 2,762 on June 10, 2026, and 2,529 on June 11, 2026.
Covista Inc.’s Chief Financial Officer, Robert J. Phelan, reported open-market sales of 5,314 shares of common stock at weighted average prices around $135 per share over two days. The sales were made under a pre-established Rule 10b5-1 trading plan adopted in December 2025 and executed in pre-scheduled increments. After these transactions, he continues to hold over 50,000 shares directly, consistent with Covista’s stock ownership and holding requirements and a policy that allows no discretionary insider sales.
Covista Inc. senior vice president and general counsel Douglas G. Beck reported two open-market sales of company common stock executed under a pre-established Rule 10b5-1 trading plan. He sold 2650 shares on July 7, 2026 at a weighted average price of $135.403 and 2439 shares on July 8, 2026 at a weighted average price of $135.339, for total reported sales of 5089 shares. The company notes that these trades occurred pursuant to a trading plan adopted on December 11, 2025 and represent a portion of holdings above Covista’s Stock Ownership and Holding Requirements. Following the transactions, Beck directly holds 33,070 Covista common shares, and company policy allows no discretionary sales outside such pre-established Rule 10b5-1 plans absent a hardship exception.
CVSA filed a Form 144 notice reporting a proposed sale of 7,500 Restricted Stock Units held through Morgan Stanley Smith Barney LLC. The filing also records a prior 10b5-1 sale by Robert Phelan of 10,000 common shares on 05/08/2026 for $1,262,064.69.
The notice lists the securities type as Restricted Stock Units with a grant/vesting date of 08/24/2025 and identifies the broker and exchange information shown in the excerpt.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 notice reporting a proposed sale of 9,615 shares of Common stock originally granted as Restricted Stock Units on 06/14/2022. The filing lists related 10b5-1 sales for Douglas Beck and shows dollar figures on the cover line.
Covista Inc. Chairman & CEO Stephen W. Beard reported open-market sales of 5,291 shares of common stock in mid-June. He sold 2,762 shares at a weighted average price of $130.1388 per share on June 10 and 2,529 shares at $130.7847 on June 11.
The transactions were carried out under a pre-established Rule 10b5-1 trading plan adopted on December 10, 2025, in line with Covista’s insider trading policies. Footnotes state the sales reflect only the portion of his holdings above Covista’s stock ownership and holding requirements, and that discretionary trades are not permitted outside such plans. After these sales, Beard directly holds 424,033 shares of Covista common stock.
Stephen Wayne Beard Trust filed a Rule 144 notice reporting proposed dispositions of Common Stock of ATGE. The filing lists a proposed sale of 15,874 shares (dated 05/08/2026) and 2,762 shares (dated 06/10/2026). The excerpt also records 2,529 shares acquired as restricted stock units on 09/08/2025.
Covista Inc. reported a notice of proposed sale on Form 144 for 2,762 shares of Common Stock acquired as Restricted Stock Units on 09/08/2025. The filing shows 15,874 shares sold in the past three months and an associated dollar figure of $2,083,508.53 tied to that disposition. The broker listed is Goldman Sachs & Co. LLC (New York).
Covista Inc. filed an initial Form 3 insider report for Amelia Manning, who serves as President, Chamberlain Univ. at the issuer. This filing establishes her status as a reporting officer under SEC rules. The data provided show no reported share transactions or holdings in this submission.
Covista Inc. VP and Chief Accounting Officer Gangadharan Manjunath reported a routine tax-withholding transaction. On the vesting of previously awarded restricted stock units, 426 shares of common stock were used to satisfy tax withholding obligations at an indicated value of $127.85 per share. After this non-market disposition, he continues to hold 5,271 shares of Covista common stock directly.